ATE370162T1 - Pegylierte lösliche gp130-dimere, die sich als medikament eignen - Google Patents

Pegylierte lösliche gp130-dimere, die sich als medikament eignen

Info

Publication number
ATE370162T1
ATE370162T1 AT04740207T AT04740207T ATE370162T1 AT E370162 T1 ATE370162 T1 AT E370162T1 AT 04740207 T AT04740207 T AT 04740207T AT 04740207 T AT04740207 T AT 04740207T AT E370162 T1 ATE370162 T1 AT E370162T1
Authority
AT
Austria
Prior art keywords
cells
sgp130peg
sgp130fc
microg
baf
Prior art date
Application number
AT04740207T
Other languages
English (en)
Inventor
Dirk Seegert
Stefan Schreiber
Stefan Rose-John
Georg Waetzig
Nikolaus Rahaus
Original Assignee
Conaris Res Inst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Inst Ag filed Critical Conaris Res Inst Ag
Application granted granted Critical
Publication of ATE370162T1 publication Critical patent/ATE370162T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04740207T 2003-06-23 2004-06-23 Pegylierte lösliche gp130-dimere, die sich als medikament eignen ATE370162T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20030014049 EP1491554A1 (de) 2003-06-23 2003-06-23 PEGlierte lösliche gp130-Dimeren geignet als Medikament

Publications (1)

Publication Number Publication Date
ATE370162T1 true ATE370162T1 (de) 2007-09-15

Family

ID=33395847

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04740207T ATE370162T1 (de) 2003-06-23 2004-06-23 Pegylierte lösliche gp130-dimere, die sich als medikament eignen

Country Status (9)

Country Link
US (2) US7534862B2 (de)
EP (2) EP1491554A1 (de)
JP (1) JP4745224B2 (de)
AT (1) ATE370162T1 (de)
DE (1) DE602004008273T2 (de)
DK (1) DK1636263T3 (de)
ES (1) ES2293278T3 (de)
PT (1) PT1636263E (de)
WO (1) WO2004113383A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1491554A1 (de) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGlierte lösliche gp130-Dimeren geignet als Medikament
ES2309427T3 (es) * 2004-08-27 2008-12-16 Conaris Research Institute Ag Secuencias de nucleotidos optimizidas que codifican para sgp130.
EP1801121A1 (de) 2005-12-23 2007-06-27 CONARIS research institute AG Lösliche Varianten des Moleküls gp130 nützlich als Arzneimittel
RS51544B (en) 2006-06-30 2011-06-30 Conaris Research Institute Ag. POBOLJŠANI SGP 130FC DIMERI
EP2050759A1 (de) 2007-10-19 2009-04-22 CONARIS research institute AG Lösliche gp-130-Muteine mit verbesserter Bindungsaktivität
EP2080770A1 (de) * 2008-01-21 2009-07-22 MorphoSys AG Proteinöse Bindemoleküle mit Reinigungstags
US8309688B2 (en) * 2008-12-30 2012-11-13 Centocor Ortho Biotech Inc. Monkey homolog of human oncostatin M and methods of use thereof
EP3226888B1 (de) 2014-12-01 2021-04-21 Ferring B.V. Verabreichung eines selektiven il-6-transsignalisierenden inhibitors
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
WO2018175340A1 (en) * 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
CN108070034B (zh) * 2017-12-15 2020-11-10 福州大学 人可溶性糖蛋白130单克隆抗体及编码基因、制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
JP3693671B2 (ja) * 1991-03-15 2005-09-07 アムゲン インコーポレーテッド ポリペプチドのｐｅｇ化
JPH06256394A (ja) * 1991-08-13 1994-09-13 Kirin Amgen Delaware Inc 修飾インターロイキン６
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
AU3830895A (en) * 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
DK1148065T3 (da) * 2000-04-21 2008-04-28 Conaris Res Inst Ag Fusionsproteiner omfattende to oplöselige gp130-molekyler
MXPA03010649A (es) * 2001-05-21 2005-10-05 Nektar Therapeutics Administracion pulmonar de insulina modificada quimicamente.
EP1491554A1 (de) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGlierte lösliche gp130-Dimeren geignet als Medikament

Also Published As

Publication number Publication date
DE602004008273T2 (de) 2008-05-08
EP1636263A2 (de) 2006-03-22
PT1636263E (pt) 2007-11-21
DK1636263T3 (da) 2007-12-17
JP2007526745A (ja) 2007-09-20
WO2004113383A2 (en) 2004-12-29
US7534862B2 (en) 2009-05-19
EP1491554A1 (de) 2004-12-29
US20070270334A1 (en) 2007-11-22
WO2004113383A3 (en) 2005-06-23
US20080227155A1 (en) 2008-09-18
JP4745224B2 (ja) 2011-08-10
DE602004008273D1 (de) 2007-09-27
EP1636263B1 (de) 2007-08-15
US7629147B2 (en) 2009-12-08
ES2293278T3 (es) 2008-03-16

Similar Documents

Publication Publication Date Title
ATE370162T1 (de) Pegylierte lösliche gp130-dimere, die sich als medikament eignen
Standiford et al. IL-4 inhibits the expression of IL-8 from stimulated human monocytes.
De La Luz Sierra et al. Differential processing of stromal-derived factor-1α and stromal-derived factor-1β explains functional diversity
Martin et al. IL-1 family antagonists in mouse and human skin inflammation
Metzemaekers et al. Regulation of chemokine activity–a focus on the role of dipeptidyl peptidase IV/CD26
Luger et al. IFN-beta 2/IL-6 augments the activity of human natural killer cells.
Mantovani et al. The chemokine system in diverse forms of macrophage activation and polarization
Schiraldi et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4
Mantovani et al. The origin and function of tumor-associated macrophages
Kato et al. The roles of IFN-γ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts
Reinhold et al. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor‐β1 in PWM‐stimulated PBMC and T cells
Brenne et al. Interleukin-21 is a growth and survival factor for human myeloma cells
Delgado et al. Rapid inactivation of stromal cell‐derived factor‐1 by cathepsin G associated with lymphocytes
Aung et al. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma
Luger et al. Epidermal cytokines
Gruber et al. Macrophage-colony-stimulating factor expression by anti-CD45 stimulated human monocytes is transcriptionally up-regulated by IL-1 beta and inhibited by IL-4 and IL-10.
CA2531322A1 (en) A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
De Zutter et al. The role of post-translational modifications of chemokines by CD26 in cancer
Kibata et al. The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells
Pantic et al. The frog skin host-defense peptide frenatin 2.1 S enhances recruitment, activation and tumoricidal capacity of NK cells
DE602006015103D1 (de) Als medikament geeignete lösliche varianten des gp130-moleküls
Reinhold et al. CD26 Mediates the Action of HIVA Tat Protein on DNA Synthesis and Cytokine Production in U937 Cells
Leeuwenberg et al. Interferon beta 1, an intermediate in the tumor necrosis factor alpha-induced increased MHC class I expression and an autocrine regulator of the constitutive MHC class I expression.
US20080305097A1 (en) Use of Protease or a Protease Inhibitor for the Manufacture of Medicaments
Lazzarino et al. IL-8 and MCP-1 secretion is enhanced by the peptide-nucleic acid immunomodulator, product R, in U937 cells and primary human monocytes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1636263

Country of ref document: EP

REN Ceased due to non-payment of the annual fee